Janssen Must Pay $150 Million in Whistleblowers’ Drug Suit (1)

A New Jersey jury determined that Janssen Products LP owes $150 million for violating the federal False Claims Act and various state FCAs by improperly billing governments for HIV drugs.

Janssen caused almost 160,000 false claims to be submitted to the governments through its unlawful promotion of Prezista or Intelence, according to a jury verdict form in the suit before the US District Court for the District of New Jersey.

Janssen owes $120 million for violating the federal FCA, and $30 million for violating state FCAs, the June 13 form said.

The jury didn’t find that that Janssen violated ...